MPs Sound the Alarm UK Deals with Donald Trump are 'Unstable'.

Ministers and senior MPs have issued warnings that the United Kingdom's recent agreements with the US administration are "fundamentally unstable." This follows revelations that a recently announced deal on medicines, which commits to zero tariffs in exchange for the NHS paying more, lacks any underlying contract beyond broad headline terms contained within government press releases.

An Agreement in Principle Only

The US-UK pharmaceuticals agreement, hailed as a "generational" achievement, exists as an "agreement in principle" without detailed provisions. It has been highlighted that the press releases from the UK and US governments present the deal in markedly contrasting terms. The British version celebrates securing "zero per cent tariffs" as a unique achievement, while the American announcement dwells on the commitment for the NHS to pay 25% more for new medications.

"The danger exists that the UK government has promised concessions to raise drug prices in return for only a verbal promise from President Trump," said David Henig, a trade policy analyst. "It is documented he has a record of not keeping promises."

Wider Concerns Amidst a Suspended Agreement

Concerns have been intensified by Washington's recent decision to pause the high-value digital accord, which was previously described as "a transformative pact" in the bilateral relationship. The US cited a lack of progress from the UK on addressing wider trade issues as the reason for the pause.

Furthermore, concessions agreed to for British farmers as part of an initial accord have yet to be formally approved by the US, despite a imminent January deadline. "Our understanding is that the US has not yet signed off the reciprocal tariff rate quota," said Tom Bradshaw of the National Farmers' Union.

Private Ministerial Concerns

Privately, ministers have admitted unease that the government's deals with Washington are flimsy and unreliable. One minister described the series of agreements as "built on sand," while another characterized the situation as the "prevailing condition" in the transatlantic relationship, marked by "additional layers of volatility and unpredictability."

Layla Moran, a senior MP on the health committee, argued: "The only thing more surprising than Trump's temper tantrums is the UK government's optimistic assumption that his administration is a good faith actor. The NHS is too precious to be gambled with."

Official Reassurances and Concrete Outcomes

Ministry sources have sought to reduce the possibility of the US reneging on the pharmaceuticals deal. One source noted the US pharmaceutical industry itself had been pushing for the agreement, wanting clarity on imports and pricing, making it less abstract than the paused tech deal.

Officials admit that unpredictability is inherent in dealing with the Trump administration. However, they maintain that the UK has secured concrete outcomes for businesses, such as reduced duties on automobiles compared to other nations. "Securing 25% steel tariffs, which is lower than the rate for the rest of the world, is not flimsy," one official said.

Nevertheless, problems have emerged in implementing the May tariff agreement. Promised reciprocal agricultural allowances have yet to be finalized, and the commitment to "remove tariffs on British steel and aluminium" has is still pending, with tariffs staying at 25%.

As negotiations continue, the two sides have agreed to resume talks on the paused tech prosperity deal in January, following what were described as "constructive" meetings between UK and US officials in Washington.